Buy Rating for Tenaya Therapeutics Driven by Promising Clinical Developments and Strategic Restructuring

William Blair analyst Sami Corwin has maintained their bullish stance on TNYA stock, giving a Buy rating on April 25.

Sami Corwin has given his Buy rating due to a combination of factors including Tenaya Therapeutics’ promising clinical developments and strategic restructuring. The company has made significant progress in its clinical trials, particularly with the RIDGE study, which evaluates AAV9 expression in patients with PKP2-associated ARVC. The interim results presented at a key conference highlighted the high disease burden among patients, suggesting a strong need for effective treatments.
Moreover, Tenaya’s restructuring plan, which focuses on the clinical development of TN-201 and TN-401, is expected to optimize resource allocation and extend the company’s financial runway into the second half of 2026. This strategic focus on key clinical programs, along with cost-containment measures, positions Tenaya well for future growth and supports the positive outlook reflected in the Buy rating.

In another report released on April 25, Piper Sandler also maintained a Buy rating on the stock with a $40.00 price target.

Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TNYA in relation to earlier this year.